Betterlife Pharma INC 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
OQB
BetterLife Pharma Inc. filed its annual report for the fiscal year ended January 31, 2026, detailing ongoing development efforts and financial performance.
OQB
BetterLife Pharma Inc. reported a net loss of $3.62 million for the fiscal year ended January 31, 2025, increasing its accumulated deficit to over $118 million, raising substantial doubt about its ability to continue as a going concern.
OQB
BetterLife Pharma Inc. announces its financial results for the fiscal year ended January 31, 2024, highlighting a decrease in net loss compared to the previous year.